ASCO GU 2023 Conference Coverage

 

Videos
07:52

ASCO GU 2023 Conference Coverage

Independent Biomarkers Predictive of Outcomes With Enfortumab Vedotin in Patients With Advanced UC: Analysis of the UNITE Study

FEATURING Tanya Jindal
  • 98 views
  • July 21, 2023
06:49

ASCO GU 2023 Conference Coverage

ASCO GU 2023 DEAR Study: Real-World Use of Darolutamide, Enzalutamide, and Apalutamide for nmCRPC

FEATURING Daniel George
  • 373 views
  • April 18, 2023
  • 2
12:39

ASCO GU 2023 Conference Coverage

Efficacy and Safety of Darolutamide in Combination With ADT and Docetaxel by Disease Volume and Disease Risk in the Phase 3 ARASENS Study

FEATURING Cora Sternberg
  • 1,353 views
  • March 30, 2023
  • 4
08:18

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Effectiveness of Darolutamide in mCRPC

FEATURING Alyssa Liang
  • 123 views
  • March 21, 2023
05:39

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Analysis of the UNITE Study: Biomarkers of Response to Enfortumab Vedotin in Patients With Advanced Urothelial Carcinoma

FEATURING Tanya Jindal
  • 103 views
  • March 16, 2023
11:07

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Innovative and Pragmatic Methods to Study BCG-Unresponsive NMIBC

FEATURING John Gore
  • 51 views
  • March 13, 2023
  • 1
07:09

ASCO GU 2023 Conference Coverage

ASCO GU 2023 HER2 Expression in Urothelial Carcinoma

FEATURING Vadim Koshkin
  • 87 views
  • March 10, 2023
07:23

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Response & Outcomes of Maintenance Avelumab After Platinum-Based Chemotherapy in Patients With Advanced Urothelial Carcinoma: Real-World Experience

FEATURING Petros Grivas, Dimitra Bakaloudi
  • 253 views
  • March 10, 2023
  • 1
10:44

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Additional Results From the Randomized Phase 2 CheckMate 650 Trial: Nivo + Ipi for the Treatment of Post-Chemotherapy mCRPC

FEATURING Russell Pachynski
  • 305 views
  • March 9, 2023
  • 1
07:06

ASCO GU 2023 Conference Coverage

ASCO GU 2023 JAVELIN Bladder 100 Trial: Avelumab 1L Maintenance for Advanced Urothelial Carcinoma - Long-Term Follow-Up in Subgroups Defined by 1L Chemo Regimen & Analysis of OS From Start of 1L Chemo

FEATURING Kala Sridhar
  • 261 views
  • March 8, 2023
  • 2
05:40

ASCO GU 2023 Conference Coverage

ASCO GU 2023 International Phase 3 Randomised Controlled PACE-A Trial: Comparing SBRT to Surgery for Localized Prostate Cancer - Primary Endpoint Analysis

FEATURING Nicholas van As
  • 101 views
  • March 8, 2023
08:32

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Assessment of AR-LBD Mutations in mCRPC

FEATURING Emmanuel Antonarakis
  • 64 views
  • March 8, 2023
  • 1
07:36

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Assessment of Clavien-Dindo Classification in Patients With Metastatic Clear Cell RCC Who Received Perioperative Cabozantinib and Nivolumab on the Cyto-KIK Clinical Trial

FEATURING Karie Runcie
  • 88 views
  • March 8, 2023
05:31

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II AlphaBet Trial: Evaluating the Combination of Radium-223 and [177Lu]Lu-PSMA-I&T in Patients With mCRPC

FEATURING Arun Azad
  • 59 views
  • March 2, 2023
  • 1
04:34

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase I/II LuCAB Trial: Evaluating Cabazitaxel in Combination With [177Lu]Lu-PSMA-617 in Patients With mCRPC

FEATURING Arun Azad
  • 135 views
  • March 2, 2023
  • 1
05:20

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Efficacy of Systemic Therapy Following [177Lu]Lu-PSMA in Patients With mCRPC

FEATURING Arun Azad
  • 131 views
  • March 2, 2023
  • 1
03:05

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Adjuvant Therapies in Renal Cell Carcinoma: Are New Data Practice-Changing

FEATURING Matthew Zibelman
  • 264 views
  • March 1, 2023
  • 1
05:47

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Outcomes by IMDC Risk in the COSMIC-313 Phase 3 Trial: Evaluating Cabozantinib + Nivo & Ipi in 1L Advanced RCC of IMDC Intermediate or Poor Risk

FEATURING Thomas Powles
  • 211 views
  • March 1, 2023
07:03

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Evidence From Four High-Volume Institutions: Characteristics of Long-Term Responder Patients Treated With Androgen-Receptor Signaling Inhibitors as a 1L Treatment for mCRPC

FEATURING Orazio Caffo
  • 42 views
  • February 28, 2023
10:24

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Real-World Data from an Italian Multicenter Observational Study - ECHOS Trial: Outcomes of Post-Progression Therapies in Patients With mCSPC Progressing After Docetaxel

FEATURING Orazio Caffo
  • 47 views
  • February 28, 2023
  • 1
07:49

ASCO GU 2023 Conference Coverage

ASCO GU 2023 First Analysis From an Italian Multicenter Observational Study - ECHOS Trial: Real-World Outcomes of Docetaxel in mCSPC Patients

FEATURING Orazio Caffo
  • 109 views
  • February 28, 2023
  • 1
12:48

ASCO GU 2023 Conference Coverage

Cost-Effectiveness Analysis of Seven Treatment Regimens in mHSPC: A Public Payer Perspective Using Network Meta-Analysis

FEATURING Manish Kohli
  • 243 views
  • February 28, 2023
  • 2
07:53

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase 3 IMvigor130 Study: Final OS Analysis of Atezo Monotherapy vs. Chemo in Untreated Locally Advanced or Metastatic Urothelial Carcinoma

FEATURING Aristotelis Bamias
  • 93 views
  • February 28, 2023
13:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Interim Analysis of the Prospective Phase II COTRIMS Trial: Retroperitoneal Lymphadectomy in Metastatic Seminoma

FEATURING Axel Heidenreich
  • 94 views
  • February 28, 2023
  • 1
09:47

ASCO GU 2023 Conference Coverage

FDA Announcement Based on the MAGNITUDE Trial: Niraparib With Abiraterone Acetate and Prednisone in Patients With mCRPC and Homologous Recombination Repair Gene Alterations

FEATURING Eleni Efstathiou
  • 197 views
  • February 28, 2023
01:46

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blind Phase 3 KEYNOTE-921 Study: Pembro + Docetaxel for Patients With mCRPC

FEATURING Daniel Petrylak
  • 281 views
  • February 28, 2023
  • 1
08:45

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Machine-Learning to Predict Utility of ctDNA for Somatic Genotyping

FEATURING Cameron Herberts
  • 29 views
  • February 28, 2023
04:49

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Updated Outcomes in TROPHY-U-01 Cohort 1-A Phase 2 Study of SG in Pts With mUC That Progressed After PT-Based Chemo and a CPI

FEATURING Scott Tagawa
  • 167 views
  • February 23, 2023
05:48

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Randomized Double-Blinded Phase II Study of Keto HC and Anti-PSMA Antibody J591 Labeled With 177Lu or 111In in Pts With High-Risk nmCRPC

FEATURING Scott Tagawa
  • 41 views
  • February 23, 2023
14:09

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Exposure Toxicity and Response Relationship of Cabozantinib in Patients With mRCC

FEATURING Yann-Alexandre Vano
  • 90 views
  • February 23, 2023
04:20

ASCO GU 2023 Conference Coverage

ASCO GU 2023 CaboPoint Phase 2 Study: Cabozantinib After Checkpoint Inhibitor Therapy in Patients With Advanced RCC

FEATURING Laurence Albiges
  • 128 views
  • February 23, 2023
05:32

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Cell-Free utDNA to Detect MRD Prior to Repeat-Transurethral Resection of Bladder Tumor in NMIBC

FEATURING Kyle Rose
  • 77 views
  • February 22, 2023
  • 1
14:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Active Surveillance for Favorable Intermediate-Risk Prostate Cancer

FEATURING Anthony D'Amico
  • 153 views
  • February 22, 2023
12:05

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Novel Guidelines for PSMA PET Staging of Prostate Cancer: When to Follow and When to Not

FEATURING David Nanus
  • 329 views
  • February 22, 2023
  • 3
12:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Sequential Enfortumab Vedotin After Platinum-Based Chemo in Metastatic or Locally Advanced Urothelial Cancer: Complete Response, Bladder Preservation, and Survival

FEATURING Putao Cen
  • 251 views
  • February 21, 2023
08:15

ASCO GU 2023 Conference Coverage

ASCO GU 2023 3-Year Follow-Up From The Phase 3 CheckMate 9ER Trial: Nivolumab + Cabozantinib vs. Sunitinib for 1L Treatment of Advanced RCC

FEATURING Mauricio Burotto
  • 369 views
  • February 21, 2023
15:17

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Systemic Therapy for Recurrent Metastatic RCC: Beyond Second Line

FEATURING Tian Zhang
  • 827 views
  • February 21, 2023
  • 4
02:42

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Three Highlights With Resident Jindal and Dr. Park

FEATURING Tanya Jindal, Chandler Park
  • 37 views
  • February 20, 2023
22:25

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Prostate and Bladder Updates With Dr. Jones and Dr. Park

FEATURING Robert Jones, Chandler Park
  • 129 views
  • February 18, 2023
09:22

ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Grivas Discuss TROPHY-U-01 and EV-201 Trials in Metastatic Urothelial Carcinoma

FEATURING Petros Grivas, Chandler Park
  • 661 views
  • February 18, 2023
  • 2
08:13

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Plimack and Dr. Park Discuss Over-Treating in Muscle Invasive Bladder Cancer

FEATURING Elizabeth R. Plimack, Chandler Park
  • 627 views
  • February 18, 2023
08:59

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Treatment Outcomes With New Targeted Agents in Advanced Urothelial Carcinoma - UNITE Study With Dr. Koshkin and Dr. Park

FEATURING Vadim Koshkin, Chandler Park
  • 221 views
  • February 18, 2023
06:04

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Phase II Study Rucaparib Monotherapy in Pts With nmHSPC With a “BCRAness” Genotype With Dr. Sahu and Dr. Park

FEATURING Kamal Sahu, Chandler Park
  • 113 views
  • February 18, 2023
06:34

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Flaig and Dr. Park Discuss Updates in Prostate and Bladder Cancer

FEATURING Thomas Flaig, Chandler Park
  • 446 views
  • February 18, 2023
  • 2
05:18

ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Miron and Dr. Park Discuss Kidney and Bladder Updates

FEATURING Ben Miron, Chandler Park
  • 509 views
  • February 18, 2023
  • 1
06:19

ASCO GU 2023 Conference Coverage

ASCO GU 2023: Dr. Park and Dr. Gupta Discuss the BLASST-1 Study

FEATURING Shilpa Gupta, Chandler Park
  • 229 views
  • February 18, 2023
09:12

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Longitudinal Detection of ctDNA in Patients With Advanced Renal Cell Carcinoma Featuring Dr. Basu and Dr. Park

FEATURING Arnab Basu, Chandler Park
  • 249 views
  • February 18, 2023
  • 1
03:08

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day Two Highlights With Dr. Talukder and Dr. Park

FEATURING Rafee Talukder, Chandler Park
  • 35 views
  • February 17, 2023
10:32

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Dr. Rettig and Dr. Park Discuss Prostate Cancer Updates

FEATURING Matthew Rettig, Chandler Park
  • 223 views
  • February 17, 2023
  • 1
05:57

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Comparison of ctDNA Between African-American and Caucasian Patients With CRPC Post-Abiraterone and/or Enzalutamide

FEATURING Albert Jang, Chandler Park
  • 242 views
  • February 16, 2023
10:01

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Bladder Cancer Highlights With Dr. Sonpavde and Dr. Park

FEATURING Guru Sonpavde, Chandler Park
  • 620 views
  • February 16, 2023
  • 1
01:53

ASCO GU 2023 Conference Coverage

ASCO GU 2023 Day One Highlights With Dr. Zakharia

FEATURING Yousef Zakharia
  • 83 views
  • February 16, 2023
  • 1